6 results about "Skeletal muscle cell" patented technology

The present invention relates to a composition comprising sialyloligosaccharide and N-acetylmannosamine for the treatment of GNE myopathy, and a method of using same. Despite ManNac exhibiting non-significant sialylation activity in GNE knockdown (GNE KD) C2C12 skeletal muscle cells, it was confirmed that co-administration of ManNac and sialyloligosaccharide promotes sialylation more effectively than single administration, thereby exhibiting an excellent synergistic effect. Such effects have also been confirmed in an animal model of GNE myopathy, and thus the combined therapy of ManNAc and sialyloligosaccharide of the present invention is expected to be advantageously employed as a novel therapeutic approach capable of overcoming hyposialylation caused by sialic acid deficiency in GNE myopathy.

The application discloses a use and application based on CDKN1A influence on proliferation and differentiation of goat skeletal muscle, relates to the field of agricultural genetic engineering, and discloses that iRNA-seq and RNA-seq technology reveals mRNA expression maps of the longest dorsal muscle of 5-month-old Hainan black goats and 24-month-old Hainan black goats in two development stages, and CDKN1A with differential expression is screened out; the CDKN1A gene is used for negatively regulating proliferation of goat myoblasts; and the application finds that CDKN1A has a regulation effect on proliferation and differentiation of skeletal muscle cells of Hainan black goats, and can be applied to development and utilization of germplasm resources of the breed and seed selection and breeding.

The present application discloses the use of SUR2 receptor modulators. In the present application, SUR2 receptor modulators (e.g. MLC1) can be combined with skeletal muscle cell K ATP SUR2 specific binding on potassium ion channel, thus enhancing intracellular calcium signal, increasing glucose uptake of skeletal muscle cell and reducing blood glucose, and thus can be used as a therapeutic drug for diabetes; SUR2 receptor modulators selectively bind to SUR2 through a non-islet β cell dependent mechanism, and have no inhibitory effect on islet β cell SUR1 receptor, and thus can effectively avoid hypoglycemia while reducing blood glucose, and have small side effects.

This invention relates to the application of *Hirudo medicinalis* in the preparation of drugs that promote skeletal muscle cell differentiation and / or prevent muscle atrophy, belonging to the field of biomedical technology. The skeletal muscle cells are myoblasts. In vitro, this drug can promote differentiation by upregulating the expression of myosin heavy chain (MyHC), myogenin, and myogenic determinant MyoD, thereby increasing myotube diameter. In vivo, it can improve doxorubicin-induced skeletal muscle atrophy in mice and repair muscle fiber damage caused by natural aging nematodes. The chemotherapeutic drug is doxorubicin, which can exert an anti-atrophy effect by maintaining the expression of myosin heavy chain (MyHC) and improving myotube morphology damage. This invention is the first to discover and experimentally demonstrate that *Hirudo medicinalis* freeze-dried powder has the activity of promoting myoblast differentiation and preventing muscle atrophy, opening up new applications for traditional Chinese medicine leeches in the prevention and treatment of muscle atrophy and expanding the medicinal value of *Hirudo medicinalis*.

The application describes methods for producing artificial skeletal muscle tissue from pluripotent stem cells. A method for producing skeletal myoblasts, skeletal myotubes and satellite cells from pluripotent stem cells is also disclosed. During the described methods, there is directed differentiation and maturation of the pluripotent stem cells into skeletal myotubes and satellite cells. The application also describes artificial skeletal muscle tissue which has multinuclear skeletal muscle fibres with satellite cells. Furthermore, the invention relates to mesodermally differentiated skeletal myoblast precursor cells, myogenically specified skeletal myoblast precursor cells, skeletal myoblast cells, satellite cells and skeletal myotubes, which can be produced by means of the disclosed methods. The application also describes the use of skeletal muscle tissue or the disclosed cells in drug testing or in medicine. Lastly, the application relates to in vitro methods in which the skeletal muscle tissue or the disclosed cells are used.

The application discloses a method for preparing LCORL gene edited bovine cells based on CRISPR, and the method comprises the following steps: constructing a specific sgRNA expression vector for a bovine LCORL gene, and performing precise base mutation modification on a target region of the LCORL gene of bovine skeletal muscle cells by using a CRISPR gene editing system, so that a bovine skeletal muscle cell line with a LCORL gene site-directed mutation is successfully obtained. The bovine skeletal muscle cell line with the LCORL gene base mutation is prepared for the first time, and the blank in the construction of the bovine skeletal muscle cell line with the LCORL gene is filled. Meanwhile, four different types of LCORL gene edited cell lines are created. The LCORL gene edited cell lines can be more directly and effectively used for analyzing the regulation path and the action mechanism of the LCORL gene in the improvement of bovine meat production traits. The obtained gene edited cell lines have good stability, and can provide new technical support and experimental basis for subsequent breeding of high growth performance beef cattle breeds.